| Autor: |
Maria C. Buscarinu, Francesca Gargano, Luana Lionetto, Matilde Capi, Emanuele Morena, Arianna Fornasiero, Roberta Reniè, Anna C. Landi, Giulia Pellicciari, Carmela Romano, Rosella Mechelli, Silvia Romano, Giovanna Borsellino, Luca Battistini, Maurizio Simmaco, Corrado Fagnani, Marco Salvetti, Giovanni Ristori |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Frontiers in Neurology, Vol 12 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1664-2295 |
| DOI: |
10.3389/fneur.2021.683398 |
| Popis: |
Background: The changes of the gut-brain axis have been recently recognized as important components in multiple sclerosis (MS) pathogenesis.Objectives: To evaluate the effects of DMF on intestinal barrier permeability and mucosal immune responses.Methods: We investigated intestinal permeability (IP) and circulating CD161+CCR6+CD8+T cells in 25 patients with MS, who met eligibility criteria for dimethyl-fumarate (DMF) treatment. These data, together with clinical/MRI parameters, were studied at three time-points: baseline (before therapy), after one (T1) and 9 months (T2) of treatment.Results: At baseline 16 patients (64%) showed altered IP, while 14 cases (56%) showed active MRI. During DMF therapy we found the expected decrease of disease activity at MRI compared to T0 (6/25 at T1, p = 0.035 and 3/25 at T2, p < 0.00), and a reduction in the percentage of CD161+CCR6+CD8+ T cells (16/23 at T2; p < 0.001). The effects of DMF on gut barrier alterations was variable, without a clear longitudinal pattern, while we found significant relationships between IP changes and drop of MRI activity (p = 0.04) and circulating CD161+CCr6+CD8+ T cells (p = 0.023).Conclusions: The gut barrier is frequently altered in MS, and the CD161+ CCR6+CD8+ T cell-subset shows dynamics which correlate with disease course and therapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
